<template xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="openEHR/v1/Template">  <id>f8215e2f-9ba0-4b93-8862-b24c6303ab64</id>  <name>Graft vs Host Disease Adult Order Set</name>  <description>    <lifecycle_state>Initial</lifecycle_state>    <details>      <purpose />      <use />      <misuse />    </details>    <other_details>      <item>        <key>MetaDataSet:Sample Set </key>        <value>Template metadata sample set </value>      </item>      <item>        <key>Acknowledgements</key>        <value />      </item>      <item>        <key>Business Process Level</key>        <value />      </item>      <item>        <key>Care setting</key>        <value />      </item>      <item>        <key>Client group</key>        <value />      </item>      <item>        <key>Clinical Record Element</key>        <value />      </item>      <item>        <key>Copyright</key>        <value />      </item>      <item>        <key>Issues</key>        <value />      </item>      <item>        <key>Owner</key>        <value />      </item>      <item>        <key>Sign off</key>        <value />      </item>      <item>        <key>Speciality</key>        <value />      </item>      <item>        <key>User roles</key>        <value />      </item>    </other_details>  </description>  <annotations path="[openEHR-EHR-SECTION.adhoc.v1]">    <items>      <item>        <key>Technical.ﻩ Technical Traceability</key>        <value>{~AHSID~f8215e2f-9ba0-4b93-8862-b24c6303ab64~NAME~Graft vs Host Disease Adult Order Set}</value>      </item>    </items>  </annotations>  <annotations path="[openEHR-EHR-SECTION.adhoc.v1]/items[openEHR-EHR-SECTION.clinical_guidance.v1]">    <items>      <item>        <key>Transform.Technical Notes</key>        <value>&lt;p&gt;Order Set Keywords: Oncology, Cancer, GVHD, BMT&lt;/p&gt;</value>      </item>      <item>        <key>CKT.Clinical Guidance</key>        <value>&lt;p&gt;&amp;nbsp;&lt;/p&gt;&lt;p&gt;&lt;em&gt;Consider Opening and merging the following order sets:&lt;/em&gt;&lt;/p&gt;&lt;p&gt;&lt;em&gt;- Adult Oncology Admission&lt;/em&gt;&lt;/p&gt;&lt;p&gt;&lt;em&gt;- Oncology Supportive Care Symptom Management&lt;/em&gt;&lt;/p&gt;&lt;p&gt;&amp;nbsp;&lt;/p&gt;&lt;p&gt;Refer to the &lt;u&gt;&lt;strong&gt;Alberta Bone Marrow and Blood Cell Transplant Program: Standard Practice Manual &lt;/strong&gt;&lt;/u&gt;for guidance (URL: https://ahsweb.ca/HEE/AB_Bone_Marrow_Blood_Cell_Transplant_Program_Manual)&lt;/p&gt;&lt;p&gt;&amp;nbsp;&lt;/p&gt;</value>      </item>    </items>  </annotations>  <annotations path="[openEHR-EHR-SECTION.adhoc.v1]/items[openEHR-EHR-SECTION.adhoc.v1 and name/value='General']/items[openEHR-EHR-SECTION.clinical_guidance.v1 and name/value='Clinical Decision Support - Acute']">    <items>      <item>        <key>CKT.Clinical Guidance</key>        <value>&lt;p&gt;&lt;u&gt;&lt;strong&gt;Acute GVHD&lt;/strong&gt;&lt;/u&gt;&lt;/p&gt;&lt;table border="1" cellspacing="0" cellpadding="0" style="width:852px"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;Stage&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;Skin&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;Liver&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top; width:334px"&gt;&lt;p&gt;Gut&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;No rash&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;Total bilirubin &amp;lt; 34 umol/L&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top; width:334px"&gt;&lt;p&gt;No diarrhea&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;Maculopapular rash &amp;lt;25% body surface area&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;Total bilirubin 34 to 50 umol/L&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top; width:334px"&gt;&lt;p&gt;Diarrhea 500 – 1000 mL/day or nausea with positive gastric biopsy&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;Maculopapular rash 25-50% body surface area&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;Total bilirubin 51 to 100 umol/L&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top; width:334px"&gt;&lt;p&gt;Diarrhea 1000 – 1500 mL/day&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;Maculopapular rash &amp;gt;50% body surface area&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;Total bilirubin 101 to 250 umol/L&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top; width:334px"&gt;&lt;p&gt;Diarrhea 1500 – 2000 mL/day&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;Generalized exfoliative, ulcerative or bullous dermatitis&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;Total bilirubin &amp;gt; 250 umol/L&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top; width:334px"&gt;&lt;p&gt;Diarrhea &amp;gt;2000 mL/day or severe abdominal pain or ileus&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p&gt;&amp;nbsp;&lt;/p&gt;&lt;table border="1" cellspacing="0" cellpadding="0"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:top"&gt;&lt;p&gt;Stage&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;Grade&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top"&gt;&lt;p&gt;Skin&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top"&gt;&lt;p&gt;Liver&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;Gut&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;And&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;And&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;0&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;I&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;1-2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;And&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;And&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;0&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;II&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;Or&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;Or&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;1&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;III&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;2-3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;Or&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;2-4&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;IV&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;Or&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;4&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p&gt;&amp;nbsp;&lt;/p&gt;</value>      </item>    </items>  </annotations>  <annotations path="[openEHR-EHR-SECTION.adhoc.v1]/items[openEHR-EHR-SECTION.adhoc.v1 and name/value='General']/items[openEHR-EHR-SECTION.clinical_guidance.v1 and name/value='Clinical Decision Support - Chronic']">    <items>      <item>        <key>CKT.Clinical Guidance</key>        <value>&lt;p&gt;&lt;u&gt;&lt;strong&gt;Chronic GVHD&lt;/strong&gt;&lt;/u&gt;&lt;/p&gt;&lt;table border="1" cellspacing="0" cellpadding="0" style="width:0px"&gt;&lt;tbody&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;Organ Scores&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;Score 0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;Score 1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;Score 2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;Score 3&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;&lt;strong&gt;SKIN &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;No symptoms&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;&amp;lt;19% BSA with disease signs but NO sclerotic features&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;19-50% BSA OR involvement with superficial sclerotic features “not hidebound” (able to pinch)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;&amp;gt;50% BSA OR deep sclerotic features “hidebound” (not able to pinch) OR impaired mobility, ulceration, or severe pruritis&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;&lt;strong&gt;MOUTH &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;No symptoms&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;Mild symptoms with disease signs but not limiting oral intake significantly&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;Moderate symptoms with disease signs with partial limitation of oral intake&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;Severe symptoms with disease signs on examination with major limitation of oral intake&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;&lt;strong&gt;EYES &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;No symptoms&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;Mild dry eye symptoms not affecting ADL (requiring eyedrops &amp;lt; 3 times daily) OR asymptomatic signs of keratoconjunctivitis sicca&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;Moderate dry eye symptoms partially affecting ADL (requiring drops &amp;gt;3 times daily or puntal plugs) WITHOUT vision impairment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;Severe dry eye symptoms significantly affecting ADL (special eyewear to relieve pain) OR unable to work because of ocular symptoms) OR loss of vision caused by keratoconjunctivitis sicca&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;&lt;strong&gt;GI TRACT &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;No symptoms&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;Symptoms such as dysphagia, anorexia, nausea, vomiting, abdominal pain or diarrhea without significant weight loss (&amp;lt;5%)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;Symptoms associated with mild to moderate weight loss (5-15%)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;Symptoms associated with significant weight loss &amp;gt;15%, requires nutritional supplement for most calorie needs OR esophageal dilation&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;&lt;strong&gt;LIVER &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;Normal LFT&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;Bilirubin (total) normal&lt;/p&gt;&lt;p&gt;ALT 180-300 U/L&lt;/p&gt;&lt;p&gt;ALP ≥429 U/L&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;Bilirubin 24-72 umol/L&lt;/p&gt;&lt;p&gt;ALT &amp;gt;300 U/L&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;Bilirubin &amp;gt;72 umol/L&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;&lt;strong&gt;LUNGS &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;No symptoms&lt;/p&gt;&lt;p&gt;FEV1 &amp;gt;80%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;Mild symptoms (shortness of breath after climbing 1 flight of steps), or&lt;/p&gt;&lt;p&gt;FEV1 60-79%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;Moderate symptoms (shortness of breath after walking on flat ground), or&lt;/p&gt;&lt;p&gt;FEV1 40-59%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;Severe symptoms (shortness of breath at rest requiring O2), or&lt;/p&gt;&lt;p&gt;FEV1 &amp;lt;39%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;&lt;strong&gt;JOINTS &amp;amp; FASCIA &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;No symptoms&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;Mild tightness of arms or legs, normal or mild decreased range of motion AND not affecting ADL&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;Tightness of arms or legs OR joint contractures, erythema thought due to fascitis, moderate decreased range of motion AND mild to moderate limitation of ADL&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;Contractures WITH significant decrease of range of motion AND significant limitation of ADL (unable to tie shoes, button shirt, dress self)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;&lt;strong&gt;GENITAL TRACT* &lt;/strong&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;No symptoms/signs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;Mild signs*&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;Moderate signs*&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top"&gt;&lt;p&gt;Severe signs*&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/tbody&gt;&lt;/table&gt;&lt;p&gt;&lt;em&gt;*Genital signs:&lt;/em&gt;&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Female genitalia: &lt;/strong&gt;&lt;/p&gt;&lt;p&gt;1) Mild (any of the following); erythema on vulvar mucosal surfaces, vulvar lichen-planus or vulvar lichen-sclerosis.&lt;/p&gt;&lt;p&gt;2) Moderate (any of the following); erosive inflammatory changes of the vulvar mucosa, fissures in vulvar folds&lt;/p&gt;&lt;p&gt;3) Severe (any of the following); labial fusion, clitoral hood agglutination, fibrinous vaginal adhesions, circumferential fibrous vaginal banding, vaginal shortening, synechia, dense sclerotic changes, and complete vaginal stenosis.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Male genitalia: &lt;/strong&gt;&lt;/p&gt;&lt;p&gt;1) Mild: lichen planus-like feature;&lt;/p&gt;&lt;p&gt;2) Moderate: lichen sclerosus-like feature or moderate erythema;&lt;/p&gt;&lt;p&gt;3) Severe: phimosis or urethral/meatal scarring.&lt;/p&gt;&lt;p&gt;&amp;nbsp;&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Global Score: &lt;/strong&gt;&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Mild cGVHD: &lt;/strong&gt;&lt;/p&gt;&lt;p&gt;• &lt;strong&gt;≤2 organs involved with max organ score 1, plus lung score 0&lt;/strong&gt;&lt;/p&gt;&lt;p&gt;&amp;nbsp;&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Moderate cGVHD: &lt;/strong&gt;&lt;/p&gt;&lt;p&gt;• &lt;strong&gt;≥3 organs involved with max score 1, or&lt;/strong&gt;&lt;/p&gt;&lt;p&gt;• &lt;strong&gt;≥1 organ (not lung) with a score of 2, or&lt;/strong&gt;&lt;/p&gt;&lt;p&gt;• &lt;strong&gt;Lung score 1&lt;/strong&gt;&lt;/p&gt;&lt;p&gt;&amp;nbsp;&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Severe cGVHD: &lt;/strong&gt;&lt;/p&gt;&lt;p&gt;• &lt;strong&gt;≥1 organ with a score of 3, or&lt;/strong&gt;&lt;/p&gt;&lt;p&gt;• &lt;strong&gt;Lung score 2 or 3&lt;/strong&gt;&lt;/p&gt;</value>      </item>    </items>  </annotations>  <annotations path="[openEHR-EHR-SECTION.adhoc.v1]/items[openEHR-EHR-SECTION.adhoc.v1 and name/value='Patient Care']/items[openEHR-EHR-SECTION.adhoc.v1]/items[openEHR-EHR-INSTRUCTION.service_request.v1]/activities[at0001]">    <items>      <item>        <key>CKT.Content Details</key>        <value>&lt;p&gt;&amp;nbsp; Ensure stool output is recorded every shift&lt;/p&gt;</value>      </item>    </items>  </annotations>  <annotations path="[openEHR-EHR-SECTION.adhoc.v1]/items[openEHR-EHR-SECTION.adhoc.v1 and name/value='Medications']/items[openEHR-EHR-SECTION.adhoc.v1 and name/value='Clinical Decision Support']/items[openEHR-EHR-SECTION.clinical_guidance.v1]">    <items>      <item>        <key>CKT.Clinical Guidance</key>        <value>&lt;p&gt;First Line Treatment of Acute GVHD is corticosteriods.&lt;/p&gt;&lt;p&gt;Second Line Treatment of Acute GVHD (Steroid-Refractory) is Ruxolitnib (Ruxolitinib is currently a non-formulary medication, it is available off the facility list as needed, starting dose typically 10 mg, oral, 2 times per day).&lt;/p&gt;</value>      </item>    </items>  </annotations>  <annotations path="[openEHR-EHR-SECTION.adhoc.v1]/items[openEHR-EHR-SECTION.adhoc.v1 and name/value='Medications']/items[openEHR-EHR-SECTION.adhoc.v1 and name/value='Topical Agents']/items[openEHR-EHR-INSTRUCTION.service_request.v1 and name/value='betamethasone valerate Cream 0.1%; topical, 3 times per day']/activities[at0001]">    <items>      <item>        <key>CKT.Content Details</key>        <value>&lt;p&gt;&amp;nbsp;Apply sparingly to affected body areas.&lt;/p&gt;</value>      </item>    </items>  </annotations>  <annotations path="[openEHR-EHR-SECTION.adhoc.v1]/items[openEHR-EHR-SECTION.adhoc.v1 and name/value='Medications']/items[openEHR-EHR-SECTION.adhoc.v1 and name/value='Topical Agents']/items[openEHR-EHR-INSTRUCTION.service_request.v1 and name/value='hydrocortisone acetate Cream 1%; topical, 3 times per day']/activities[at0001]">    <items>      <item>        <key>CKT.Content Details</key>        <value>&lt;p&gt;&amp;nbsp; Apply to affected facial areas.&lt;/p&gt;</value>      </item>    </items>  </annotations>  <definition xsi:type="SECTION" archetype_id="openEHR-EHR-SECTION.adhoc.v1" concept_name="Ad hoc heading" max="1" name="Graft vs Host Disease Adult Order Set">    <Item xsi:type="SECTION" archetype_id="openEHR-EHR-SECTION.clinical_guidance.v1" concept_name="Clinical Guidance" path="/items" />    <Item xsi:type="SECTION" archetype_id="openEHR-EHR-SECTION.adhoc.v1" concept_name="Ad hoc heading" max="1" path="/items" name="General">      <Item xsi:type="SECTION" archetype_id="openEHR-EHR-SECTION.clinical_guidance.v1" concept_name="Clinical Guidance" max="1" path="/items" name="Clinical Decision Support - Acute" />      <Item xsi:type="SECTION" archetype_id="openEHR-EHR-SECTION.clinical_guidance.v1" concept_name="Clinical Guidance" max="1" path="/items" name="Clinical Decision Support - Chronic" />    </Item>    <Item xsi:type="SECTION" archetype_id="openEHR-EHR-SECTION.adhoc.v1" concept_name="Ad hoc heading" max="1" path="/items" name="Patient Care">      <Item xsi:type="SECTION" archetype_id="openEHR-EHR-SECTION.adhoc.v1" concept_name="Ad hoc heading" max="1" path="/items" name="Patient Care Assessments">        <Item xsi:type="INSTRUCTION" archetype_id="openEHR-EHR-INSTRUCTION.service_request.v1" template_id="c25dee98-440d-4a0f-8b2b-e1615b375cd7" concept_name="PC Intake and Output Order" max="1" path="/items" name="Intake and Output; (Stool), every shift" />      </Item>    </Item>    <Item xsi:type="SECTION" archetype_id="openEHR-EHR-SECTION.adhoc.v1" concept_name="Ad hoc heading" max="1" path="/items" name="Laboratory Investigations">      <Item xsi:type="SECTION" archetype_id="openEHR-EHR-SECTION.adhoc.v1" concept_name="Ad hoc heading" max="1" path="/items" name="Therapeutic Drug Monitoring and Toxicology">        <Item xsi:type="INSTRUCTION" archetype_id="openEHR-EHR-INSTRUCTION.service_request.v1" template_id="866222b6-a0ad-4130-bc21-393c197e7c20" concept_name="LAB Cyclosporine Level Pre-dose Order" max="1" path="/items" name="Cyclosporine Level, Pre-dose; Mon/Wed/Fri Per Medication Dosing" />        <Item xsi:type="INSTRUCTION" archetype_id="openEHR-EHR-INSTRUCTION.service_request.v1" template_id="168a348b-b31f-425e-bf9b-5a7f8c29ff51" concept_name="LAB Tacrolimus Level Order" max="1" path="/items" name="Tacrolimus Level; Mon/Wed/Fri Per Medication Dosing" />        <Item xsi:type="INSTRUCTION" archetype_id="openEHR-EHR-INSTRUCTION.service_request.v1" template_id="fbad9375-d4fa-4c09-9c60-01dd6430a3e5" concept_name="LAB Sirolimus Level Order" max="1" path="/items" name="Sirolimus Level; Weekly Per Medication Dosing" />      </Item>    </Item>    <Item xsi:type="SECTION" archetype_id="openEHR-EHR-SECTION.adhoc.v1" concept_name="Ad hoc heading" max="1" path="/items" name="Medications">      <Item xsi:type="SECTION" archetype_id="openEHR-EHR-SECTION.adhoc.v1" concept_name="Ad hoc heading" max="1" path="/items" name="Clinical Decision Support">        <Item xsi:type="SECTION" archetype_id="openEHR-EHR-SECTION.clinical_guidance.v1" concept_name="Clinical Guidance" path="/items" />      </Item>      <Item xsi:type="SECTION" archetype_id="openEHR-EHR-SECTION.adhoc.v1" template_id="40067c2f-d4b1-428f-bc57-68bc7baaf0db" concept_name="Corticosteroid aGVHD first line treatment oncology adult order group" max="1" path="/items" name="Corticosteroids" />      <Item xsi:type="SECTION" archetype_id="openEHR-EHR-SECTION.adhoc.v1" template_id="49233d16-118b-4dc9-8557-8312c7439548" concept_name="Immunosuppressive Agents Oncology Adult Order Group" max="1" path="/items" name="Immunosuppressive Agents" />      <Item xsi:type="SECTION" archetype_id="openEHR-EHR-SECTION.adhoc.v1" concept_name="Ad hoc heading" max="1" path="/items" name="Topical Agents">        <Item xsi:type="INSTRUCTION" archetype_id="openEHR-EHR-INSTRUCTION.section_supporting_context.v1" concept_name="Section supporting context" path="/items" />        <Item xsi:type="INSTRUCTION" archetype_id="openEHR-EHR-INSTRUCTION.service_request.v1" template_id="68478d78-bb7b-431c-8470-45234d1e6f77" concept_name="PHARM betamethasone valerate Cream 0.1% Order" max="1" path="/items" name="betamethasone valerate Cream 0.1%; topical, 3 times per day" />        <Item xsi:type="INSTRUCTION" archetype_id="openEHR-EHR-INSTRUCTION.service_request.v1" template_id="32f6be99-5710-4516-bbe7-fdd2016c92e2" concept_name="PHARM hydrocortisone acetate Cream 1% Order" max="1" path="/items" name="hydrocortisone acetate Cream 1%; topical, 3 times per day" />        <Item xsi:type="INSTRUCTION" archetype_id="openEHR-EHR-INSTRUCTION.service_request.v1" template_id="f1133e85-8cd4-4835-8a35-21a337082f0a" concept_name="PHARM cycloSPORINE Oral liquid 100 mg/mL Order" max="1" path="/items" name="cycloSPORINE Oral liquid 100 mg/mL; 5 mL, swish and spit, 4 times per day" />        <Item xsi:type="INSTRUCTION" archetype_id="openEHR-EHR-INSTRUCTION.service_request.v1" template_id="9cc7f7fc-f36b-44b3-a569-ba28fe6de1d7" concept_name="PHARM betamethasone sodium phosphate Enema 5 mg/100 mL Order" max="1" path="/items" name="betamethasone sodium phosphate Enema 5 mg/100 mL; 10 mLs, swish and spit, 4 times per day" />      </Item>      <Item xsi:type="SECTION" archetype_id="openEHR-EHR-SECTION.adhoc.v1" concept_name="Ad hoc heading" max="1" path="/items" name="Ophthalmic Drops">        <Item xsi:type="INSTRUCTION" archetype_id="openEHR-EHR-INSTRUCTION.service_request.v1" template_id="ecba7cad-75a6-46d7-b0f9-abb2c0ef4998" concept_name="PHARM prednisoLONE acetate Eye drop 1% Order" max="1" path="/items" name="prednisoLONE acetate Eye drop 1%; 2 drops, BOTH eyes, 3 times per day, as scheduled" />        <Item xsi:type="INSTRUCTION" archetype_id="openEHR-EHR-INSTRUCTION.section_supporting_context.v1" concept_name="Section supporting context" path="/items" />      </Item>    </Item>  </definition>  <integrity_checks xsi:type="ArchetypeIntegrity" archetype_id="openEHR-EHR-SECTION.adhoc.v1">    <digest id="MD5-CAM-1.0.1">8AE70853975A75254E6D39A8DE3652AF</digest>  </integrity_checks>  <integrity_checks xsi:type="ArchetypeIntegrity" archetype_id="openEHR-EHR-SECTION.clinical_guidance.v1">    <digest id="MD5-CAM-1.0.1">4B2F0F6CD593E442DA9C30277A3EA9CF</digest>  </integrity_checks>  <integrity_checks xsi:type="ArchetypeIntegrity" archetype_id="openEHR-EHR-INSTRUCTION.service_request.v1">    <digest id="MD5-CAM-1.0.1">AD8DFB192E67715F0D9E11E95E674AD0</digest>  </integrity_checks>  <integrity_checks xsi:type="ArchetypeIntegrity" archetype_id="openEHR-EHR-CLUSTER.service_request_information.v1">    <digest id="MD5-CAM-1.0.1">230A8D964017E1FD7AC82EBDEE0202A6</digest>  </integrity_checks>  <integrity_checks xsi:type="ArchetypeIntegrity" archetype_id="openEHR-EHR-SECTION.orderable_section.v1">    <digest id="MD5-CAM-1.0.1">A89AC74BC8CAD3F0719579389C69006F</digest>  </integrity_checks>  <integrity_checks xsi:type="ArchetypeIntegrity" archetype_id="openEHR-EHR-INSTRUCTION.section_supporting_context.v1">    <digest id="MD5-CAM-1.0.1">A7EC4E4C870D8C3431B29F6514353416</digest>  </integrity_checks>  <integrity_checks xsi:type="ArchetypeIntegrity" archetype_id="openEHR-EHR-CLUSTER.booleanorderquestion.v1">    <digest id="MD5-CAM-1.0.1">56B5A2F2979B94F83C97E66B46679692</digest>  </integrity_checks>  <integrity_checks xsi:type="ArchetypeIntegrity" archetype_id="openEHR-EHR-CLUSTER.datetimeorderquestion.v1">    <digest id="MD5-CAM-1.0.1">37AE50193A7EA542A4F219FF051EE95B</digest>  </integrity_checks>  <integrity_checks xsi:type="ArchetypeIntegrity" archetype_id="openEHR-EHR-CLUSTER.freetextorderquestion.v1">    <digest id="MD5-CAM-1.0.1">5DC6E2FC9E91ADD05E7C5B3E06F83D23</digest>  </integrity_checks></template>